Health Care Supply Chains: COVID-19 Challenges and Pressing Actions
Authors: Prakash Mirchandani
Journal: Annals of Internal Medicine (2020)

Ideas and Opinions5 May 2020Health Care Supply Chains: COVID-19 Challenges and Pressing ActionsFREEPrakash Mirchandani, MBA, PhDPrakash Mirchandani, MBA, PhDUniversity of Pittsburgh, Pittsburgh, Pennsylvania (P.M.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-1326 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The coronavirus disease 2019 (COVID-19) outbreak has exposed significant glitches in health care supply chains, which are complex and highly fragmented. Health care requires 5 categories of products: pharmaceuticals, personal protective equipment, medical devices, medical supplies, and blood. Each of these categories has a distinct supply chain, and the failure of any 1 of these chains can wreak havoc on the health care system.PharmaceuticalsDrugs have long life cycles, their supply chain is global, and pharmaceutical imports are high—44% for branded and 38% for generic drugs—and increasing (1). Many active pharmaceutical ingredients are manufactured only overseas. An estimated two thirds (2) of the active ingredients of generic drugs used in the United States come from China. Italy, Belgium, and the United Kingdom are in the top 10 by dollar value of U.S. pharmaceutical imports (3), as well as by number of reported COVID-19 deaths per capita. Regulatory restrictions and virus-related manufacturing issues are disrupting global supply chains for pharmaceuticals. The United States has benefited so far from a substantial pipeline inventory, which is the result of long supply chains, batch manufacturing (which averts cross-contamination), large-scale production, and 3 months' worth (1) of stockpiled inventory at U.S. pharmaceutical companies. Once this pipeline inventory is depleted, however, shortages could follow. The immediate action plan should be to actively monitor drug supplies—not only within the United States but also back to tier 2 and 3 suppliers. End-to-end transparency will give us advance warning when upstream disruptions occur. A longer-term solution is to reshore drug manufacturing for critical drugs, or at least to develop a dual supply chain in which three fourths of the domestic demand is met by domestic production. This will improve the traceability, resiliency, and responsiveness of our pharmaceutical supply chain.Personal Protective EquipmentHealth care providers treating patients with COVID-19 must be fully protected with gowns, gloves, masks, and face shields. In early March, the nation's emergency stockpile had 12 million N95 respirators (4). The stockpile level should have been much higher, as evidenced by standard analysis of opportunity costs. Because U.S. manufacturing capacity is limited, it would take more than 4 months to fill the need for 300 million respirators (5); this limitation has put providers at risk. Although capacity has increased, new guidance from the Centers for Disease Control and Prevention has increased demand from the general public. The upshot is that providers are now forced to reuse protective masks. States, hospital systems, and the federal government are all competing for the same resources and paying a significant premium over list price—which can be prevented if these entities coordinate their plans. In the long run, a judiciously maintained emergency stockpile, rotated to keep inventory fresh, will prevent this situation from recurring.Medical DevicesMedical devices have highly regulated supply chains (6). This is both a blessing and a curse: It ensures product functionality, reliability, and quality, but it keeps prices prohibitive. In addition, high entry barriers stifle competition, innovation, and commoditization. For instance, the United States has about 160 000 ventilators (7). Accurately forecasting demand is difficult because of the fluidity of the pandemic situation and the uncertainty surrounding ventilator effectiveness for COVID-19. But shortfalls can be costly, and limited capacity is hampering the few approved U.S. manufacturers from increasing production. Lack of standardization across brands exacerbates this problem (7). Whereas supply chains for computers, automobiles, and smartphones use interchangeable components, ventilators require specially manufactured components, so scaling up capacity is difficult. Augmenting capacity by involving manufacturers from other industries is a good first step. It is also necessary to try new methods, such as 3D printing, which is more versatile and could potentially utilize capacity in university laboratories. Recent initiatives to develop open-source ventilators can help establish alternate supply chains in the short run (although product reliability is at risk). It is also crucial to remember that user interfaces differ across ventilators; they are not like laptops or automobiles, for which switching brands is easy. Acclimatizing to different ventilators places an unnecessary burden on health care professionals, wresting valuable time and energy from patient care. Moreover, switching ventilators for successive patients may result in avoidable inefficiencies. Locations with various ventilator types will require a wider array of replacement parts, increasing the likelihood of mismatches between part availability and need. Therefore, coordinated procurement across the entire U.S. health care system is essential so that homogeneity of ventilators is maintained at each location. Looking ahead, we must create a more agile supply chain for ventilators and other critical medical devices by improving product design and judiciously relaxing underlying regulations.Medical SuppliesMedical supplies consist of testing materials, laboratory and intravenous kits, surgical center supplies, and other items, and they constitute a significant proportion of the total expense in a health system (8). Supply chain issues have frustrated response strategies. For example, only 2 companies supply the nasopharyngeal swabs needed to collect testing samples (9). Newer tests and alternate testing protocols (10) are helping now, but building redundancy and developing contingency plans for medical supplies will help prepare us better for the next lethal virus.BloodBlood has a unique supply chain, theoretically comprising billions of supply points and millions of demand points. Donations are mostly voluntary, with indirect reciprocity as a motive: If I help someone today, someone else may help a loved one or me sometime later. Voluntary donations work well in normal times, but they are problematic now. Blood supplies are low. Social distancing measures make collection at hospitals and community centers difficult, and some potential donors are unwilling to visit blood collection centers. Despite the obvious expense, decentralized collection—with centralized storage and distribution to address demand variability across different hospitals—seems to be the most viable option.The implications of COVID-19 for the health care supply chains are powerful and far-reaching. Urgent action must be taken to ensure that our supply chains support our health care providers at this critical time and in the future.References1. Spitzer D. Pharmaceutical manufacturing in the U.S. IBISWorld Industry Reports 32541a; 32541b. March 2020; November 2019. Accessed at www.ibisworld.com on 24 April 2020. Google Scholar2. Roos R. Experts say COVID-19 will likely lead to US drug shortages. University of Minnesota Center for Infectious Disease Research and Policy. 27 March 2020. Accessed at www.cidrap.umn.edu/news-perspective/2020/03/experts-say-covid-19-will-likely-lead-us-drug-shortages on 24 April 2020. Google Scholar3. United States International Trade Commission. Trade data: general imports. HTC 30 (pharmaceutical products). Accessed at https://dataweb.usitc.gov on 24 April 2020. Google Scholar4. Goodnough A. Some hospitals are close to running out of crucial masks for coronavirus. The New York Times. 9 March 2020. Accessed at www.nytimes.com/2020/03/09/health/coronavirus-n95-face-masks.html on 24 April 2020. Google Scholar5. Hufford A. 3M CEO on N95 masks: ‘demand exceeds our production capacity.' The Wall Street Journal. 2 April 2020. Accessed at www.wsj.com/articles/3m-ceo-on-n95-masks-demand-exceeds-our-production-capacity-11585842928 on 24 April 2020. Google Scholar6. Curran J. Medical device manufacturing in the U.S. IBISWorld Industry Report 33451b. April 2020. Accessed at https://clients1-ibisworld-com.pitt.idm.oclc.org/reports/us/industry/competitivelandscape.aspx?entid=764 on 24 April 2020. Google Scholar7. Baldwin W. Ventilator maker: we can ramp up production five-fold. Forbes. 14 March 2020. Accessed at www.forbes.com/sites/baldwin/2020/03/14/ventilator-maker-we-can-ramp-up-production-five-fold/#10246ae65e9a on 24 April 2020. Google Scholar8. Abdulsalam Y, Schneller E. Hospital supply expenses: an important ingredient in health services research. Med Care Res Rev. 2019;76:240-252. [PMID: 29148349] doi:10.1177/1077558717719928 CrossrefMedlineGoogle Scholar9. Chang A. Swab manufacturer works to meet ‘overwhelming' demand. All Things Considered. 1 April 2020. Accessed at www.npr.org/sections/coronavirus-live-updates/2020/04/01/825499508/one-of-the-few-manufacturers-of-the-special-swab-for-coronavirus-tests-speaks on 24 April 2020. Google Scholar10. Zimmer C. Yale researchers find spit might be the key to widespread COVID-19 testing. Yale News. 23 April 2020. Accessed at https://yaledailynews.com/blog/2020/04/23/yale-researchers-find-spit-might-be-the-key-to-widespread-covid-19-testing on 24 April 2020. Google Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Prakash Mirchandani, MBA, PhDAffiliations: University of Pittsburgh, Pittsburgh, Pennsylvania (P.M.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-1326.Corresponding Author: Prakash Mirchandani, MBA, PhD, University of Pittsburgh, Mervis 358, Roberto Clemente Drive, Pittsburgh, PA 15260; e-mail, pmirchan@katz.pitt.edu.Author Contributions: Conception and design: P. Mirchandani.Analysis and interpretation of the data: P. Mirchandani.Drafting of the article: P. Mirchandani.Critical revision of the article for important intellectual content: P. Mirchandani.Final approval of the article: P. Mirchandani.Administrative, technical, or logistic support: P. Mirchandani.Collection and assembly of data: P. Mirchandani.This article was published at Annals.org on 5 May 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTime to intubation with McGrath™ videolaryngoscope versus direct laryngoscope in powered air-purifying respirator: a randomised controlled trialFactors to vaccine cold chain management for sustainable and resilient healthcare deliveryUse of Digital Technology to Deal With COVID-19Cyber-susiliency index: A comprehensive resiliency-sustainability-cybersecurity index for healthcare supply chain networksImpact of the COVID-19 Pandemic on Medical Product Procurement, Prices, and Supply Chain in Zimbabwe: Lessons for Supply Chain ResiliencyPreparing for Future Pandemics and Public Health Emergencies: An American College of Physicians Policy Position PaperJosh Serchen, BA, Katelan Cline, BA, Suja Mathew, MD, and David Hilden, MD, MPH, for the Health and Public Policy Committee of the American College of Physicians, Suja Mathew, MD, David Hilden, MD, MPH, Micah Beachy, DO, William Curry, MD, Matthew Hollon, MD, MPH, Cynthia Jumper, MD, MPH, Pranav Mellacheruvu, Marianne Parshley, MD, Ankita Sagar, MD, MPH, Jamar Slocum, MD, Michael Tan, MD, Vanessa Van Doren, MD, Elham Yousef, MDA new shape of the supply chain during the COVID-19 pandemicIndustry 4.0 adoption for healthcare supply chain performance during COVID-19 pandemic in Brazil and India: the mediating role of resilience abilities developmentResilience development and digitalization of the healthcare supply chain: an exploratory study in emerging economiesTransitioning Up to Best Practice, or Down to the Bare Minimum? Global Harmonisation of Regulation of Therapeutic GoodsMeasures for the viable agri-food supply chains: A multi-criteria approachTranslational design for limited resource settings as demonstrated by Vent-Lock, a 3D-printed ventilator multiplexerSustainable supply chain operation under COVID-19: influences and response strategiesApplication of Technology in HealthcareMitigating personal protective equipment (PPE) supply chain disruptions in pandemics – a system dynamics approachComprehensive Analysis of the COVID-19: Based on the Social-Related Indexes From NUMBEOAn Eye on COVID: Hurricane Preparedness at a COVID-19 Alternative Care SiteImpact of the First Phase of the COVID-19 Pandemic on the Acquisition of Goods and Services in the Italian Health SystemAn Information Management System for the COVID-19 Pandemic Using BlockchainA Review of Supply Chain Management Practices: The Case of Botswana State-Owned Enterprises (SOE)Redesigning and Repurposing Healthcare Facilities for the New Normal, COVID-19: A Review on New Approaches in Hospital SystemsProvision of pharmaceutical care to suspected high-risk COVID-19 patients through telehealth: a nationwide simulated patient studySevere Adaptive Immune Suppression May Be Why Patients With Severe COVID-19 Cannot Be Discharged From the ICU Even After Negative Viral TestsWillingness and ability of oral health care workers to work during the COVID-19 pandemicPraxis of Technology and Tools in COVID-19 ResponseEthical challenges of nurses related COVID-19 pandemic in inpatient wards: An integrative reviewLearning from pandemics: Applying resilience thinking to identify priorities for planning urban settlementsSupply Chains and the COVID‐19 Pandemic: A Comprehensive FrameworkCovid-19 Pandemisinde Düzce Universitesi Tıp Fakültesi Mezuniyet Öncesi Eğitiminin Deneyimleri ve Pandemi Sürecinin Eğitime YansımalarıTackling COVID-19 Using Blockchain TechnologyAll Hands-On Deck and All Decks on Hand: Surmounting Supply Chain Limitations During the COVID-19 PandemicApplication of Technology in HealthcareBuilding a hemodiafiltration system from readily available components for continuous renal replacement therapy under disasters and pandemics: preparing for an acute kidney injury surge during COVID-19 18 August 2020Volume 173, Issue 4Page: 300-301KeywordsBloodCOVID-19DrugsHealth careHealth care providersPatientsPersonal protective equipmentRespiratorsSocial distancingVentilators ePublished: 5 May 2020 Issue Published: 18 August 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...